XML 27 R19.htm IDEA: XBRL DOCUMENT

Additional Information to the Items of Profit or Loss (Tables)

6 Months Ended

Jun. 30, 2018

		Six months ended June 30,					Three months ended June 30,					Year ended December 31,
		2018			2017		2018			2017		2017
		Unaudited										Audited
		USD in thousands

a.	Research and Development Expenses:

	Clinical studies	$	372		$	256	$	118		$	163	$	511
	R&D and preclinical studies		423			158		268			119		362
	Wages and related expenses		335			140		127			57		321
	Share-based payment		80			24		33			11		103
	Regulatory and other expenses		384			117		104			105		276
	Chemistry and formulation studies		51			-		-			-		330

			1,645			695		650			455		1,943

b.	General and Administrative Expenses:

	Investor relations and business expenses		164			388		55			340		871
	Professional and director fees		713			394		259			302		1,007
	Regulatory expenses		35			53		20			29		80
	Business development		484			-		393			-		74
	Wages and related expenses		347			343		120			185		808
	Office, maintenance, rent and other expenses		100			87		48			55		211
	Share-based payment		296			111		105			60		759

			2,139			1,376		1,000			971		3,810

c.	Finance income:

	Exchange rate differences		(316	)		-		(228	)		-		(1	)
	Finance income due to interest and valuation of the convertible loan		(205	)		-		(205	)		-		-
	Interest income on bank deposits		(4	)		-		(4	)		-		-

			(525	)		-		(437	)		-		(1	)

d.	Finance expenses:

	Exchange rate differences		-			426		-			435		486
	Finance expenses from interest and commissions		3			2		1			2		5

		$	3		$	428	$	1		$	437	$	491